Immunotherapy, Targeted Drugs, Brain Cancer Research Among Highlights at Cancer Meeting

Gordon Freeman 150

Eagerly awaited new data from trials of immunotherapy drugs, vaccines to treat brain tumors, and improved treatments for blood cancers sparked waves of optimism at the year’s biggest cancer meeting. The 2015 annual meeting of the American Society of Clinical Oncology (ASCO) drew about 30,000 cancer specialists to Chicago May 29 – June 2. Immunotherapy, which uses drugs to block immune “checkpoints” such as PD-1 and PD-L1, allowing the patient’s immune system to attack cancer cells, drew standing-room-only audiences as researchers reported updated results in studies of melanoma, lung cancer, and brain cancer. Investigators from Dana-Farber and Dana-Farber/Boston Children’s Cancer …

Continue reading

ASCO: New Advances in Ovarian, Prostate, Lung and Melanoma Treatment


“Science and Society” was the theme of this year’s American Society of Clinical Oncology (ASCO) 50th annual meeting. The meeting showcased  cancer research from around the world. Some new findings from Dana-Farber researchers included: Joyce Liu, MD, MPH, of the Susan F. Smith Center for Women’s Cancers reported that, in a phase 2 clinical trial, a combination of olaparib (a drug that blocks DNA repair in cancer cells) and cediranib (which blocks blood vessel growth in tumors) was considerably more effective in women with recurrent ovarian cancer than olaparib alone.. Progression-free survival – the length of time after treatment when …

Continue reading